Protein C News and Research

RSS

Potential treatment approach to new COVID-19 variant

Researchers in the United States have demonstrated a potential new approach to treating infection with the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

7 Jan 2021

Researchers provide comprehensive molecular characterization of head and neck cancers

In what is believed to be the most comprehensive molecular characterization to date of the most common type of head and neck cancer, researchers from the Johns Hopkins departments of pathology and oncology, the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine, and 18 other centers around the U.S. and Poland have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues.

7 Jan 2021

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.

7 Jan 2021

Common gene expression changes at target tissues of four autoimmune diseases found

Autoimmune diseases are diseases of "mistaken identity", where the immune system - which is supposed to protect us against infectious diseases and neoplasias - mistakenly attacks and destroys components of our own body.

7 Jan 2021

Study opens the way for a potential new cure for children with hard-to-treat neuroblastoma

Researchers at the University of Gothenburg now suggest a possible cure for children with hard-to-treat forms of neuroblastoma using a new combination of drugs.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

7 Jan 2021

CytoDel successfully delivers neuronal antibody in animal models of botulism

CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here.

7 Jan 2021

New approach can help identify novel treatments for autoimmune diseases

A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center's Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for autoimmune diseases requires studying together the immune system AND target tissues.

7 Jan 2021

Study reveals molecular machinery that regulates membrane association of Arf proteins

The small GTPases of the ADP-ribosylation factor (Arf) family are key initiators of various physiological processes including secretion, endocytosis, phagocytosis, and signal transduction. Arf family proteins function to mediate the recruitment of cytosolic effectors to specific subcellular compartments.

7 Jan 2021

Researchers examine the role of Shiga toxin in the immune system

E. coli food poisoning is one of the worst food poisonings, causing bloody diarrhea and kidney damage. But all the carnage might be just an unintended side effect, researchers from UConn Health report in the 27 November issue of Science Immunology.

7 Jan 2021

New peptide can target specific pathogen without damaging the good bacteria

Drug-resistant bacteria could lead to more deaths than cancer by 2050, according to a report commissioned by the United Kingdom in 2014 and jointly supported by the U.K. government and the Wellcome Trust.

7 Jan 2021

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Researchers who studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19 report these patients' immune memory to the virus - across all immune cell types studied - was measurable for up to 8 months after symptoms appeared.

7 Jan 2021

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to have a zoonotic origin, perhaps originating in a bat coronavirus with an unknown intermediate host. It is not only very infectious but has been found to infect a wide range of mammals, including dogs, cats, ferrets, hamsters, and minks, besides non-human primates. This range may be still higher, claims a recent preprint that appeared in January 2021 on the bioRxiv server.

6 Jan 2021

Adaptive immune system against COVID-19 can last for at least eight months

New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection.

6 Jan 2021

Study investigates control mechanism that ensures accurate chromosome inheritance during cell division

Starting as a single cell, organisms undergo millions of generations of divisions to ultimately generate the bones, heart, brain and other components that make up a living being.

6 Jan 2021

More stringent measures may be needed to control new SARS-CoV-2 B.1.1.7 variant in England

Researchers in the UK have conducted a comprehensive epidemiologic analysis of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in an effort to learn more about the expanded range and frequency of coronavirus disease 2019 (COVID-19) cases in England.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

First steps toward uncovering CRISPR/Cas gene doping in plasma

All athletes want to be at the top of their game when they compete, but some resort to nefarious approaches to achieve peak muscle growth, speed and agility. Recent developments in gene editing technology could tempt athletes to change their DNA to get an edge.

6 Jan 2021

Groundbreaking technology could revolutionize the dairy industry

Might a new technological development of researchers from Tel Aviv University soon revolutionize the dairy products we consume?

6 Jan 2021

Protein C News and Research

Potential treatment approach to new COVID-19 variant

Researchers provide comprehensive molecular characterization of head and neck cancers

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Common gene expression changes at target tissues of four autoimmune diseases found

Study opens the way for a potential new cure for children with hard-to-treat neuroblastoma

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

CytoDel successfully delivers neuronal antibody in animal models of botulism

New approach can help identify novel treatments for autoimmune diseases

Study reveals molecular machinery that regulates membrane association of Arf proteins

Researchers examine the role of Shiga toxin in the immune system

New peptide can target specific pathogen without damaging the good bacteria

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

Adaptive immune system against COVID-19 can last for at least eight months

Study investigates control mechanism that ensures accurate chromosome inheritance during cell division

More stringent measures may be needed to control new SARS-CoV-2 B.1.1.7 variant in England

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

First steps toward uncovering CRISPR/Cas gene doping in plasma

Groundbreaking technology could revolutionize the dairy industry

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News